TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07037901: A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Sponsor: Inmagene LLC · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 405 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$1,986,600

Rescue Site Savings

+$1,315,800

Unlock Full NCT07037901 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07037901 Rescue Dossier →